Japan Pushing Forward In Global Scrum For Cancer Leads
This article was originally published in PharmAsia News
Executive Summary
Japan is forging ahead with a national project to elucidate cancer-related gene alterations in its population, both to identify responder patients for possible inclusion in clinical trials for targeted therapies and to inform the development of new treatments.
You may also be interested in...
Will RWD Get Real In Japan? Govt Moves To Build Digital Health Records
To enable broader use of clinical data in its digital health care system, Japan has kickstarted digitization measures to link all patient records to an online individual ID system. While the government aims to allow real-world data and evidence for the pharmaceutical sector in the long run, Scrip explores the reality of current projects and measures in the country.
Will RWD Get Real In Japan? Govt Moves To Build Digital Health Records
To enable broader use of clinical data in its digital health care system, Japan has kickstarted digitization measures to link all patient records to an online individual ID system. While the government aims to allow real-world data and evidence for the pharmaceutical sector in the long run, The Pink Sheet explores the reality of current projects and measures in the country.
Japan’s All-Genome Project Hopes To Push Pharma R&D
Japan is aiming for the betterment of pharma R&D and medical services for rare disease patients by building a database connecting genome analysis data and clinical records. While several clinical studies are planned for the next couple of years, there are also concerns around the actual trickle-down of benefits to patients and data privacy.